Valuation: Brooks Laboratories Limited

Market Cap 170.44Cr 1.8Cr 1.6Cr 1.48Cr 1.34Cr 2.51Cr 2.55Cr 18Cr 7.06Cr 89Cr 6.74Cr 6.59Cr 281.54Cr P/E 2025
-28.6x
P/E 2026 4.45x
Enterprise Value 172.28Cr 1.81Cr 1.62Cr 1.5Cr 1.36Cr 2.54Cr 2.58Cr 18Cr 7.13Cr 90Cr 6.81Cr 6.67Cr 284.58Cr EV / Sales 2025
3.93x
EV / Sales 2026 1.3x
Free-Float
45.16%
Yield 2025 *
-
Yield 2026 -
16/09 Brooks Laboratories Limited Announces Resignation of Krutika Rane as Company Secretary and Compliance Officer (Key Managerial Personnel), Effective October 9, 2026 CI
13/08 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
17/07 Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026 CI
19/06 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
29/05 Brooks Laboratories appoints Prashant Rathi as CEO RE
29/05 Brooks Laboratories names Prashant Rathi as CEO RE
29/05 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
29/05 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
06/02 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
16/25/16 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
13/25/13 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
28/25/28 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
13/25/13 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
1 day-5.29%
1 week-14.37%
Current month+3.69%
1 month-5.15%
3 months-12.31%
6 months-10.10%
Current year-27.80%
1 week 56.7
Extreme 56.7
69.4
1 month 52.97
Extreme 52.97
75.6
Current year 36.3
Extreme 36.3
82.44
1 year 36.3
Extreme 36.3
119.41
3 years 36.3
Extreme 36.3
198.86
5 years 36.3
Extreme 36.3
198.86
10 years 13.85
Extreme 13.85
198.86
Manager TitleAgeSince
Chief Executive Officer 58 23/01/2002
Chief Executive Officer - 01/06/2026
President 58 23/08/2023
Director TitleAgeSince
Director/Board Member 53 23/11/2022
Director/Board Member 62 10/09/2010
Director/Board Member - 23/08/2023
Change 5-day change 1-year change 3-year change Capi.($)
-5.29%-14.37%-52.42%-47.99% 1.8Cr
-2.54%+1.31%+55.10%+120.84% 1,13500Cr
-1.42%+3.23%+37.07%+74.26% 64TCr
+0.16%+0.08%+25.14%+97.36% 50TCr
-0.31%+3.09%+43.92%+64.55% 38TCr
-1.34%-0.47%+66.63%+40.56% 36TCr
-0.68%+2.65%+22.46%+51.48% 29TCr
-1.20%+3.04%+2.62%+26.97% 27TCr
-1.79%+1.57%+49.97%+60.87% 24TCr
-0.73%-0.10%+29.24%+101.19% 19TCr
Average -1.13%+0.51%+27.97%+59.01% 40.04TCr
Weighted average by Cap. -0.26%+2.66%+40.99%+82.13%

Financials

2025 2026
Net sales 83Cr 86.97L 77.66L 71.74L 65.02L 1.22Cr 1.24Cr 8.63Cr 3.42Cr 43Cr 3.26Cr 3.19Cr 136.37Cr 86Cr 90.32L 80.65L 74.51L 67.52L 1.26Cr 1.28Cr 8.97Cr 3.55Cr 45Cr 3.39Cr 3.32Cr 141.62Cr
Net income -9.97Cr -10.5L -9L -9L -8L -14.69L -14.93L -1.04Cr -41.27L -5.22Cr -39.4L -38.57L -16Cr 25Cr 25.9L 23.13L 21.36L 19.36L 36.22L 36.82L 2.57Cr 1.02Cr 13Cr 97.19L 95.12L 41Cr
Net Debt 7.54Cr 8L 7L 7L 6L 11.11L 11.29L 78.84L 31.21L 3.95Cr 29.81L 29.17L 12Cr 1.84Cr 2L 2L 2L 1L 3L 3L 19.28L 8L 96.6L 7L 7L 3.05Cr
Projected Income Statement - Annual - Brooks Laboratories Limited
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company. The Company specializes in supplying pharmaceutical products to government bodies, healthcare institutions, and large organizations. It operates through two segments, which include manufacturing and trading. The manufacturing segment comprises its own manufacturing operations and loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries. The trading segment comprises principal-to-principal trading activities in pharmaceutical products, ingredients, and intermediaries. Its General Products offerings include Liquid Injection (Ampoules), Liquid Injection (Vials), Dry Powder Injections (Vials), Lyophilised Injections, Eye/Ear Drops, and Nasal Drops. The Company's Critical Care Division (CCD), operates through a robust distribution network, delivering injectables to hospitals and healthcare institutions across India.
Employees
347
Date Price Change Volume
23/26/23 ₹57.86 -5.29% 99,200
22/26/22 ₹61.09 +0.51% 54,438
21/26/21 ₹60.78 -6.59% 74,347
19/26/19 ₹65.07 -3.70% 47,904
16/26/16 ₹67.57 -4.05% 1,22,176
  1. Stock Market
  2. Stocks
  3. BROOKS Stock